Voyager Therapeutics, Inc. (VYGR) financial statements (2021 and earlier)

Company profile

Business Address 75 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments282156169174194
Cash and cash equivalents8647323731
Short-term investments195109138138163
Prepaid expense01110
Contract with customer, asset18 
Other current assets21 00
Other undisclosed current assets25231
Total current assets:305162172179196
Noncurrent Assets
Operating lease, right-of-use asset28
Property, plant and equipment18131083
Long-term investments and receivables211130
Long-term investments211130
Other undisclosed noncurrent assets21120
Total noncurrent assets:5015131134
TOTAL ASSETS:355177184190229
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26111374
Accounts payable41111
Accrued liabilities22101163
Deferred revenue47
Deferred revenue and credits3720
Contract with customer, liability21
Other liabilities3    
Total current liabilities:7632161424
Noncurrent Liabilities
Liabilities, other than long-term debt17999354036
Deferred revenue and credits344036
Deferred revenue147
Contract with customer, liability92
Deferred rent credit 6
Other liabilities321100
Total noncurrent liabilities:17999354036
Total liabilities:255131505460
Stockholders' equity
Stockholders' equity attributable to parent10046134136169
Common stock00000
Additional paid in capital412316295226219
Accumulated other comprehensive loss(0)(0)(0)(0)(0)
Accumulated deficit(313)(269)(161)(90)(50)
Total stockholders' equity:10046134136169
TOTAL LIABILITIES AND EQUITY:355177184190229

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1048101417
Cost of revenue
(Financial Services Costs)
    (10)
Gross profit:104810148
Operating expenses(156)(99)(82)(56)(38)
Other undisclosed operating income    10
Operating loss:(52)(91)(72)(41)(20)
Nonoperating income8311 
Other nonoperating income (expense)2(1)(0)0 
Interest and debt expense    (9)
Loss from continuing operations before income taxes:(44)(88)(71)(40)(30)
Income tax expense (benefit) 0 (0) 
Net loss attributable to parent:(44)(88)(71)(40)(30)
Preferred stock dividends and other adjustments    (9)
Net loss available to common stockholders, diluted:(44)(88)(71)(40)(38)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(44)(88)(71)(40)(30)
Comprehensive loss:(44)(88)(71)(40)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(44)(88)(71)(40)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: